Pancreatic Adenocarcinoma

On this page

Epidemiology & Risk Factors - Silent Pancreas Peril

  • Incidence: ~10-12 cases per 100,000 annually; high mortality.
  • Age: Predominantly >60 years (peak 70-80). Sex: Slight male predilection (M:F ~1.3:1).
  • Key Risk Factors:
    • Cigarette smoking (doubles risk; RR ~2-3x)
    • Chronic pancreatitis (RR 5-15x)
    • Diabetes Mellitus (long-standing, >5 yrs)
    • Obesity (BMI >30 $kg/m^2$)
    • Family history (1st-degree relative)
    • Inherited genetic syndromes (e.g., BRCA1/2, Peutz-Jeghers)

⭐ Smoking is the most significant, modifiable risk factor, accounting for ~25% of cases.

Pathogenesis & Genetics - Genes Gone Wild

  • Precursors: PanIN (Pancreatic Intraepithelial Neoplasia, commonest, graded 1-3), IPMN, MCN.
  • Key Mutations (sequential accumulation):
    • KRAS: >90% (oncogene, earliest).
    • CDKN2A (p16): ~90% (tumor suppressor).
    • TP53: ~70-75% (tumor suppressor).
    • SMAD4 (DPC4): ~50-55% (tumor suppressor, ↑metastasis).
    • 📌 Mnemonic: "King Charles Plays Solo" (KRAS, CDKN2A, TP53, SMAD4).
  • Hereditary Risk: BRCA1/2, PALB2, Peutz-Jeghers, Lynch, PRSS1. Pancreatic cancer progression and genetic alterations

⭐ SMAD4 loss: late event, specific, linked to poor prognosis & widespread metastasis.

Clinical Features - Telltale Pancreas Pains

  • Pain (Head/Body):
    • Epigastric, dull, boring; often radiates to the back.
    • Typically worse at night and when supine; relieved by leaning forward.
  • Painless Jaundice: 📌 Courvoisier's Law (palpable, non-tender gallbladder + jaundice suggests malignancy, not stones).
  • Weight Loss: Significant, progressive, often with anorexia.
  • Migratory Thrombophlebitis: 📌 Trousseau's sign.
  • New-onset Diabetes Mellitus (DM), especially in those >50 years. Trousseau's Syndrome migratory thrombophlebitis

⭐ New-onset DM in patients >50 years can be an early manifestation of pancreatic cancer, sometimes preceding diagnosis by months to years.

Diagnosis & Staging - Spotting the Shadow

  • Presentation: Painless jaundice (head), epigastric pain radiating to back, weight loss. Courvoisier's sign (palpable, non-tender GB).
  • Tumor Marker: CA 19-9 ↑ (e.g., >37 U/mL; very high, >1000 U/mL, suggests unresectability/mets). Not for screening.
  • Imaging: Multiphase CECT (pancreatic protocol) is key: shows hypodense mass, "double duct sign", vascular involvement, metastases.
    • Pancreatic Cancer Diagnostic Pathway
  • EUS: Best for small tumors (<2cm), detailed T/N staging, and FNA biopsy.
  • Biopsy: EUS-FNA preferred for histological proof, esp. for neoadjuvant therapy or unresectable cases.
  • Staging: AJCC TNM. Defines Resectable, Borderline Resectable, Unresectable disease.

⭐ Courvoisier's Law: Palpable, non-tender gallbladder + jaundice → suspect malignancy (e.g., pancreatic head), not just stones.

Management - Pancreas Combat Plan

  • Core Strategy: Multimodal approach: Surgery, Chemotherapy (Neoadjuvant/Adjuvant/Palliative), ± Radiotherapy (RT). Goal: R0 resection.
  • Treatment based on Resectability:
    • Resectable:
      • Surgery: Pancreaticoduodenectomy (Whipple) for head; Distal pancreatectomy ± splenectomy for body/tail.
      • Adjuvant Chemo: $mFOLFIRINOX$ or $Gemcitabine + Capecitabine\ (GemCap)$. Duration: 6 months.
    • Borderline Resectable:
      • Neoadjuvant Therapy (Chemo ± RT) to downstage.
      • Regimens: $FOLFIRINOX$, $Gemcitabine + Nab-Paclitaxel$.
      • Re-assess for surgery.
    • Locally Advanced/Unresectable (No Mets):
      • Definitive Chemoradiation or Palliative Systemic Chemotherapy.
    • Metastatic:
      • Palliative Systemic Chemotherapy: $FOLFIRINOX$ ($FOLinic\ acid + Fluorouracil + IRINotecan + OXaliplatin$) or $Gemcitabine + Nab-Paclitaxel$.
      • Best supportive care.

Whipple and Distal Pancreatectomy Diagrams

  • Palliative Interventions: Endoscopic stenting (biliary/duodenal obstruction), celiac plexus neurolysis (pain), nutritional support.

⭐ For resectable pancreatic cancer, adjuvant chemotherapy with mFOLFIRINOX offers improved survival over gemcitabine monotherapy compared to older regimens or observation alone after surgery (PRODIGE 24 trial).

High‑Yield Points - ⚡ Biggest Takeaways

  • Ductal adenocarcinoma is the most common type, primarily in the pancreatic head.
  • Painless, progressive jaundice is a classic sign for head tumors; Courvoisier's law may be present.
  • CA 19-9 is the primary tumor marker, used for monitoring.
  • Smoking is the strongest modifiable risk factor.
  • Whipple procedure (pancreaticoduodenectomy) is the standard surgery for resectable head lesions.
  • Overall prognosis is poor due to late presentation and aggressive nature.
  • Common genetic mutation: KRAS (>90%).

Practice Questions: Pancreatic Adenocarcinoma

Test your understanding with these related questions

A 73-year-old woman has noticed a 10-kg weight loss in the past 3 months. She is becoming increasingly icteric and has constant vague epigastric pain, nausea, and episodes of bloating and diarrhea. On physical examination, she is afebrile. There is mild tenderness to palpation in the upper abdomen, but bowel sounds are present. Her stool is negative for occult blood. Laboratory findings include a total serum bilirubin concentration of 11.6 mg/dL and a direct bilirubin level of 10.5 mg/dL. Which of the following conditions involving the pancreas is most likely to be present?

1 of 5

Flashcards: Pancreatic Adenocarcinoma

1/10

Carcinomas situated in the _____ of the pancreas are usually larger than the head

TAP TO REVEAL ANSWER

Carcinomas situated in the _____ of the pancreas are usually larger than the head

body

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial